Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)

Tomoki Kimura, Yasushi Nagata, Hideyuki Harada, Shinya Hayashi, Yukinori Matsuo, Tsuyoshi Takanaka, Masaki Kokubo, Kenji Takayama, Hiroshi Onishi, Koichi Hirakawa, Yoshiyuki Shioyama, Takeshi Ehara

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background: To investigate the maximum tolerated dose (MTD) and recommended dose (RD) of stereotactic body radiation therapy (SBRT) for centrally located stage IA non-small cell lung cancer (NSCLC). Methods: Five dose levels, ranging from of 52 to 68 Gy in eight fractions, were determined; the treatment protocol began at 60 Gy (level 3). Each dose level included 10 patients. Levels 1–2 were indicated if more than four patients exhibited dose-limiting toxicity (DLT), which was defined as an occurrence of a grade 3 (or worse) adverse effect within 12 months after SBRT initiation. MTD was defined as the lowest dose level at which more than four patients exhibited DLT. Results: Ten patients were enrolled in the level 3 study. One patient was considered unsuitable because of severe emphysema. Therefore, nine patients were evaluated and no patient exhibited DLT. The level 3 results indicated that we should proceed to level 4 (64 Gy). However, due to the difficulty involved in meeting the dose constraints, further dose escalation was not feasible and the MTD was found to be 60 Gy. Conclusions: The RD of SBRT for centrally located stage IA NSCLC was 60 Gy in eight fractions.

Original languageEnglish
Pages (from-to)849-856
Number of pages8
JournalInternational Journal of Clinical Oncology
Volume22
Issue number5
DOIs
Publication statusPublished - 01-10-2017

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1)'. Together they form a unique fingerprint.

Cite this